Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294295 | 0.92 | CTSL (0.40) | CTSLCYP2D6CYP2C9CCR3PPARG | |
| SCHEMBL6702836 | 0.91 | CTSL (0.41) | CTSLCYP2D6CTSKCYP2C9CCR3 | |
| SCHEMBL6698646 | 0.91 | MEN1 (0.39) | CTSLCTSKCTSBCTSS | |
| SCHEMBL6695685 | 0.90 | CTSB (0.45) | CTSLCYP2D6CTSKCYP2C9CCR3 | |
| SCHEMBL6696901 | 0.89 | USP30 (0.42) | CTSLCTSKCTSBCTSS | |
| SCHEMBL6300662 | 0.89 | CTSL (0.39) | CTSLCTSKCTSBCTSS | |
| SCHEMBL6300585 | 0.89 | CTSL (0.39) | CTSLCTSKCTSBCTSS | |
| SCHEMBL6701575 | 0.88 | TRPV1 (0.44) | CTSLCYP2D6CYP2C9KLKB1 | |
| SCHEMBL6991868 | 0.87 | CTSL (0.39) | CTSLCYP2D6CTSKCYP2C9CTSB | |
| SCHEMBL6700741 | 0.85 | DRD2 (0.45) | CTSLCYP2D6CTSKCYP2C9CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1358176-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | CTSL 15/4885CYP2D6 4431/4885CTSK 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.